Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Significant Growth in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totaling 839,994 shares, an increase of 77.3% from the July 15th total of 473,657 shares. Based on an average trading volume of 24,575,177 shares, the days-to-cover ratio is presently 0.0 days. Approximately 13.7% of the shares of the stock are short sold.

Institutional Investors Weigh In On Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC acquired a new stake in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma at the end of the most recent quarter. Institutional investors and hedge funds own 11.77% of the company’s stock.

Matinas Biopharma Stock Performance

NYSEAMERICAN MTNB traded down $0.00 on Monday, reaching $0.23. The company’s stock had a trading volume of 104,551 shares, compared to its average volume of 2,154,367. Matinas Biopharma has a twelve month low of $0.22 and a twelve month high of $2.24. The stock has a market cap of $1.47 million, a PE ratio of -0.20 and a beta of 1.76. The firm’s 50 day moving average is $0.49 and its two-hundred day moving average is $0.57.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.